Lancet

Article	Citations
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	7735
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis	5061
Endothelial cell infection and endotheliitis in COVID-19	4776
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission	4706
Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	3968
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK	3639
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study	3144
Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis	2675
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial	2561
Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic	2227
Gastric cancer	2076
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial	1928
Hyperinflammatory shock in children during COVID-19 pandemic	1795
An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study	1748
Alzheimer's disease	1614
Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study	1572
Pancreatic cancer	1376
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational	1322
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study	1289
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia	1281
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants	1276
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 tr	1265
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study	1265
Parkinson's disease	1253
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	1246

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study	1235
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial	1128
Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study	1118
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial	1088
Non-alcoholic fatty liver disease	1085
Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019	1083
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic	1026
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial	1009
The 2020 report of The Lancet Countdown on health and climate change: responding to converging crises	970
Sex and gender: modifiers of health, disease, and medicine	968
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-	947
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial	943
Lung cancer	940
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study	924
Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21	919
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials	909
Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global	893
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study	882
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment	855
SARS-CoV-2 and viral sepsis: observations and hypotheses	851
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness	848
Atopic dermatitis	834
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study	832
Psoriasis	821
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials	819
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study	818
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia	774
Chronic pain: an update on burden, best practices, and new advances	768
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression	754
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study	751
Breast cancer	733
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label	719
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial	697
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence	694
1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study	686
The 2021 report of the Lancet Countdown on health and climate change: code red for a healthy future	685
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study	684
Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study	674
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey	663
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study	657
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial	641
Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry	635
Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series	630
Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study	628
Ten scientific reasons in support of airborne transmission of SARS-CoV-2	620
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (	616
Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burd	610
Offline: COVID-19 is not a pandemic	605
Hepatocellular carcinoma	590
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial	574

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study	566
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial	564
Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the Z	558
Stroke	555
The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030	547
Liver cirrhosis	542
Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in Asia Pacific and Europe	540
Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial	533
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)	530
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial	529
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial	526
Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study	523
Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss	522
Hot weather and heat extremes: health risks	506
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled,	506
Oxford–AstraZeneca COVID-19 vaccine efficacy	504
COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England	498
Chronic kidney disease	497
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial	492
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	492
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial	488
Immune checkpoint inhibitors in melanoma	488
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates	486
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis	486
Male infertility	473
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination	464
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study	458
Gout	453
Nociplastic pain: towards an understanding of prevalent pain conditions	451
Acute pancreatitis	447
The 2022 report of the Lancet Countdown on health and climate change: health at the mercy of fossil fuels	446
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial	445
Acute respiratory distress syndrome	444
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial	441
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed	440
Biliary tract cancer	436
SARS-CoV-2 variants and ending the COVID-19 pandemic	436
Low back pain	431
Bipolar disorders	429
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial	425
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial	424
Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination	422
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo	417
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis	412
Endometriosis is a chronic systemic disease: clinical challenges and novel innovations	411
Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019	410
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial	406
Iron deficiency	406
Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study	403
Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study	388
Quality of primary health care in China: challenges and recommendations	384
Retinal findings in patients with COVID-19	380
Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study	377
Pre-eclampsia	377
RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis	376
Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019	372
Irritable bowel syndrome	371
Osteoarthritis in 2020 and beyond: a Lancet Commission	369
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised cont	368
Kawasaki-like disease: emerging complication during the COVID-19 pandemic	365
Multiple myeloma	360
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021	359
Endometrial cancer	357
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals	351
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial	348
Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study	346
Ethnicity and COVID-19: an urgent public health research priority	345
Global, regional, and national prevalence estimates of physical or sexual, or both, intimate partner violence against women in 2018	345
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial	344
Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2	342
Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial	339
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials	337
COVID-19 in Brazil: “So what?”	335
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1	335
Obesity could shift severe COVID-19 disease to younger ages	335
Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis	335
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study	330
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives	326
Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenS	326
Cystic fibrosis	325

The Lancet Commission on lessons for the future from the COVID-19 pandemic	324
The Lancet Commission on the future of care and clinical research in autism	323
COVID-19: the case for health-care worker screening to prevent hospital transmission	323
Time for united action on depression: a Lancet–World Psychiatric Association Commission	320
Migraine: epidemiology and systems of care	317
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised	316
Five insights from the Global Burden of Disease Study 2019	314
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial	312
The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study	309
Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study	308
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial	306
Artificial intelligence and the future of global health	302
WHO International Standard for anti-SARS-CoV-2 immunoglobulin	302
Schizophrenia	301
Head and neck cancer	301
Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study	300
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum	293
Revisiting maternal and child undernutrition in low-income and middle-income countries: variable progress towards an unfinished agenda	289
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label,	289
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019	285
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-grou	285
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial	283
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cel	282
Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial	279
Impacts of COVID-19 on childhood malnutrition and nutrition-related mortality	277
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 stu	275
The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study	275
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial	275
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials	274
Considering BCG vaccination to reduce the impact of COVID-19	273
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial	272
Detection of SARS-CoV-2 in human breastmilk	272
Guillain-Barré syndrome	272
COVID-19: PCR screening of asymptomatic health-care workers at London hospital	270
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials	269
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controll	267
Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine	266
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose	265
Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry	265
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial	265
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality	264
Venous thromboembolism	263
Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial	263
Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study	263
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study	260
Fragmented health systems in COVID-19: rectifying the misalignment between global health security and universal health coverage	258
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial	258
Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study	257
Considerations in boosting COVID-19 vaccine immune responses	256
Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004–18	255
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial	252
Chronic pancreatitis	252
Prostate cancer	251
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients	251
Chronic obstructive pulmonary disease	247
Challenges for the female academic during the COVID-19 pandemic	245
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial	243
Sputnik V COVID-19 vaccine candidate appears safe and effective	242
SARS-CoV-2 renal tropism associates with acute kidney injury	242
Association of metabolic–bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 part	241
From race-based to race-conscious medicine: how anti-racist uprisings call us to act	240
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, ac	239
First experience of COVID-19 screening of health-care workers in England	237
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical tr	237
Functional dyspepsia	235
Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study	235
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis	234
Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study	233
Wearing face masks in the community during the COVID-19 pandemic: altruism and solidarity	232
Diagnostics for COVID-19: moving from pandemic response to control	232
Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic	231
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial	227
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications	227
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data	226
Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study	226
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial	225
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses	224
Early evidence of pronounced brain involvement in fatal COVID-19 outcomes	224
Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled tr	224
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial	223
Functional gastrointestinal disorders: advances in understanding and management	223
Anxiety disorders	223
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation	222
Amyotrophic lateral sclerosis	222
Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million p	221
Prevention and control of non-communicable diseases in the COVID-19 response	221
Physical activity behaviours in adolescence: current evidence and opportunities for intervention	221
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial	221
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	221
Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021	217
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placeb	217
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data	215
Active case finding with case management: the key to tackling the COVID-19 pandemic	214
Reducing the health effects of hot weather and heat extremes: from personal cooling strategies to green cities	214
Organ procurement and transplantation during the COVID-19 pandemic	210